阿替普酶动脉溶栓联合复方丹参注射液治疗发病时间6 h内急性脑梗死55例分析  

Efficacy and Neurological Function Analysis of Alteplase Arterial Thrombolysis Combined with Compound Danshen Injection in the Treatment of 55 Cases of Acute Cerebral Infarction Within 6 Hours of Onset time

作　　者：李鹏程 LI Pengcheng(The First People's Hospital of Zhoukou,Zhoukou Henan 466700)

机构地区：[1]周口市第一人民医院,河南周口466700

出　　处：《药品评价》2022年第21期1332-1335,共4页Drug Evaluation

摘　　要：目的:分析阿替普酶动脉溶栓联合复方丹参注射液治疗发病时间6 h内急性脑梗死(ACI)患者的疗效及对神经功能的影响。方法:选取2020年1月至2022年1月周口市第一人民医院收治的110例发病时间6 h内ACI患者为研究对象,采用随机信封法将患者分为对照组和观察组,每组各55例。对照组采用阿替普酶动脉溶栓治疗,观察组在此基础上联合复方丹参注射液治疗。比较两组临床疗效,治疗前、治疗7 d后神经功能[神经功能缺损量表(NIHSS)],生活能力[改良Barthel指数(MBI)],血清神经功能相关指标[S100B蛋白、脑源性神经营养因子(BDNF)、神经元特异性烯醇化酶(NSE)、神经生长因子(NGF)],血清纤溶系统指标[纤溶酶原激活剂抑制物-1(PAI-1)、组织型纤溶酶原激活物(t-PA)],血清半乳糖凝集素-1(Galectin-1),半乳糖凝集素-3(Galectin-3),基质金属蛋白酶-9(MMP-9),胱抑素-C(Cys-C)水平。结果:观察组临床总有效率94.55%高于对照组81.82%(P<0.05);治疗后观察组NIHSS评分较对照组低,MBI评分较对照组高(P<0.05);治疗后观察组血清S100B、NSE水平低于对照组,BDNF、NGF水平高于对照组(P<0.05);治疗后观察组血清PAI-1水平较对照组低,t-PA水平较对照组高(P<0.05);治疗后两组血清Galectin-1、Galectin-3、MMP-9、Cys-C水平均降低,且观察组低于对照组(P<0.05)。结论:阿替普酶动脉溶栓联合复方丹参注射液治疗发病时间6 h内ACI患者,能有效降低其血清Galectin-1、Galectin-3、MMP-9、Cys-C水平,改善患者神经功能,调节纤溶系统,促进患者生活能力恢复,提高治疗效果。Objective:To study the effect of alteplase intra-arterial thrombolysis combined with compound danshen injection in the treatment of patients with acute cerebral infarct(ACI)within 6 hours of onset time and its influence on neurological function.Methods:110 patients with ACI in The First People’s Hospital of Zhoukou from January 2020 to January 2022 within 6 hours of onset time were selected as the research objects,and the patients were divided into the control group and the observation group by random envelope method,with 55 cases in each group.The control group was treated with alteplase intra-arterial thrombolysis,and the observation group was treated with compound danshen injection on this basis.The clinical efficacy,neurological function[neurological deficit scale(NIHSS)],living ability[modified Barthel index(MBI)],serum neurological function-related indexes[S100B protein,brain-derived neuron Trophic factor(BDNF),neuron-specific enolase(NSE),nerve growth factor(NGF)],serum fibrinolytic system index[plasminogen activator inhibitor-1(PAI-1),tissue fibrinolytic Lysinogen Activator(t-PA)],Serum Galectin-1,Galectin-3,Matrix Metalloproteinase-9(MMP-9),Cystatin-C(Cys-C)levels.Results:The total clinical effective rate of the observation group was 94.55%higher than that of the control group 81.82%(P<0.05);after treatment,the NIHSS score of the observation group was lower than that of the control group,and the MBI score of the observation group was higher than that of the control group(P<0.05);after treatment,the serum levels of S100B and NSE in the observation group were lower than those in the control group,while the levels of BDNF and NGF were higher than those in the control group(P<0.05);after treatment,the serum PAI-1 level in the observation group was lower than that in the control group,and the t-PA level was higher than that in the control group(P<0.05);after treatment,the serum levels of Galectin-1,Galectin-3,MMP-9 and Cys-C in the two groups were decreased,and the observation group was lower than the contr

关 键 词：脑梗死 血栓溶解疗法 阿替普酶 复方丹参注射液 神经功能 纤溶系统 

分 类 号：R743.3[医药卫生—神经病学与精神病学]